Diagnostic Kit for NT-proBNP (Time-resolved Fluorescence Immunochromatographic Assay)

Primary DI

06974521000686

Basic UDI-DI Code

B-06974521000686

Reference

SUPF014025

Device Types

Single use

Regulation

Eu Ivdd

Classification

Eu Ivd General

Status

On The Market

Manufacturer

Shenzhen Superbio Technology Co.,Ltd.

This kit is suitable for in vitro quantitative detection of the concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) in human serum, plasma and whole blood. This product is used for testing in medical and health institutions as an aid in the diagnosis of heart failure and its prognosis. B-type natriuretic peptide (BNP), is mainly synthesized by ventricles. It is initially synthesized as a B-type natriuretic peptide precursor (pre-proBNP) with 134 amino acids. After that, the signal peptide of 26 amino acids at the N-terminal is cut off to form pro-B-type natriuretic peptide (proBNP) containing 108 amino acids, which is further cut into N-terminal B-type natriuretic peptide (also called N-terminal pro brain natriuretic peptide, NT-proBNP) with 76 amino acids at N-terminal and BNP with 32 amino acids at C-terminal by endopeptidase fufin. NT-proBNP and BNP are released into the blood at the same time. NT-proBNP has no biological activity. When the ventricular volume load or pressure load increases, the synthesis and release of NT-proBNP and BNP will increase, and the blood concentration of NT-proBNP will be significantly increased, which can sensitively reflect the damage of cardiac function in the early stage of heart failure. The reference value of NT-proBNP in human body is affected by age, gender and race.

Other on-the-market devices with the same classification (Eu Ivd General) and regulation (EU IVDD).